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Pulmonary hypertension in patients with end-stage renal
disease on hemodialysis is a newly described entity. To
determine its impact, we measured selected clinical variables
in the survival of 127 hemodialysis patients. Overall,
pulmonary hypertension was found in 37 of these patients; it
was already prevalent in 17 of them before initiation of
dialysis and was associated with severe cardiac dysfunction.
In the other 20 it developed after dialysis began, without
obvious cause. These two subgroups of patients had similar
survival curves, which were significantly worse in comparison
to those without pulmonary hypertension. Following the
initiation of hemodialysis, 20 patients with otherwise
matched clinical variables survived significantly longer than
the 20 who developed pulmonary hypertension after dialysis
began. With univariate analysis, significant hazard ratios were
found for age at onset of hemodialysis therapy (1.7), valvular
diseases (1.8), pulmonary hypertension prevalence before
hemodialysis (3.6) and incident after hemodialysis (2.4) for
predicting mortality. In a multivariable Cox proportional
hazard model, the development of pulmonary hypertension
both before and after initiation of hemodialysis had
significantly increased odds ratios and remained an
independent predictor of mortality. Our study shows the
incidence of pulmonary hypertension, after initiation of
hemodialysis therapy, is a strong independent predictor of
mortality nearly equal to that associated with long-standing
severe cardiac abnormalities.
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Pulmonary hypertension (PHT) is an uncommon disease
characterized by increased pulmonary artery pressure (PAP)
and resistance. The disease results from many diverse
mechanism among which the most common are cardiac,
pulmonary, and systemic diseases. PHT is associated with
increased morbidity and mortality. For example, the median
survival for untreated primary PHT patients is 30 months.
The vast majority of PHT in the population of end-stage
renal disease (ESRD) patients receiving hemodialysis (HD)
therapy through a surgical arterio-venous (A-V) access is
secondary to heart conditions. However, unexplained PHT in
this patient’s population has been described too,1–5 repre-
senting a distinct clinical syndrome in which PHT occurs
shortly after the A-V access formation, sometimes even before
starting HD therapy,6 mainly among patients with signifi-
cantly (A-V access mediated) increased cardiac output (CO),
and may regress after reduction of CO by temporary A-V
access closure or after reversing the uremia by successful
kidney transplantation.1 The pathogenesis of this syndrome
is considered to be ESRD-related endothelial dysfunction that
restricts the ability of the pulmonary vessels to accommodate
the A-V access-mediated elevated CO.3–5 In a preliminary
observation including 58 HD patients,1 we recorded higher
mortality rates among HD patients with unexplained PHT.
This study was designed to extend existing data regarding the
correlation between PHT and mortality among ESRD
patients receiving chronic HD therapy.
RESULTS
The characteristics of the entire study population and of
subgroups of patients with and without PHT are presented in
Table 1. There were 78 males and 49 females with a
male:female ratio of 1.59. The mean±s.d. and median age
at the onset of HD therapy were 61.6±14 and 63 years,
respectively. Seventy-seven percent of the patients were in the
sixth to eighth decades of life at the onset of HD therapy. The
most common etiology of the end-stage renal failure was
diabetes mellitus, which was found in 41 (32.3%) patients.
Ischemic heart disease was the most common comorbidity,
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2009 International Society of Nephrology
Received 31 October 2007; revised 17 December 2008; accepted 23
December 2008; published online 11 February 2009
Correspondence: Mordechai Yigla, Division of Pulmonary Medicine,
Rambam Health Care Campus, POB 9602, Haifa 31096, Israel.
E-mail: m_yigla@rambam.health.gov.il
Kidney International (2009) 75, 969–975 969
presenting in 58 (45.7%) patients. Ninety patients underwent
HD therapy through radial and 37 through brachial vascular
access. The mean duration of HD therapy and follow-up was
4.7±2.4 years, range 2–12 years.
Pulmonary hypertension of X45 mm Hg was found in 37
(29.1%) patients. In 17 (13.4%) of them it was present before
entering the HD program, whereas in the entire 20 patients
(15.7%) it was incident after initiation of HD therapy. These
two subgroups had similar mean systolic PAP values (52±6
vs 54±5 mm Hg, respectively, P¼ 0.37).
For patients with PHT incident after the initiation of HD
therapy, the time interval from initiation of HD to the first
echo study that showed PHT was o1 year in 15 patients
(75%) and 1–5 years in five patients (25%). Extensive work-
up failed to disclose a cause for the PHT in this subgroup of
patients.
Data about the cardiac status are shown in Table 2. Fifty-
eight patients (45.7%) had ischemic heart disease and 65
patients (51.2%) had at least one-left ventricular abnormality
—dilatation (53), hypertrophy (60), systolic dysfunction
(26), and diastolic dysfunction (38). Thirty-five patients
(27.6%) had left ventricular segmental wall abnormalities
reflecting old myocardial infarction. Thirty-three patients
(25.6%) had significant valvular abnormalities (moderate to
severe mitral regurgitation—26, and moderate to severe
aortic regurgitation—6, severe aortic stenosis—1).
The three subgroups of patients had similar clinical
characteristics with respect to gender and age distribution,
etiology of kidney failure, type and frequency of co-morbid
conditions, list of medication used, and A-V access location,
and the differences between the parameters among the three
subgroups were not statistically significant (Table 1). As
shown in Table 2, patients without PHT and with PHT
incident after initiation of HD therapy had similar cardiac
status as reflected by the frequency of ischemic heart disease
and by the distribution of echocardiographic abnormalities,
Table 1 | Patient characteristics
All No PHT PHT prevalent on entering HD PHT incident after initiation of HD
No. of patients 127 90 (70.9%) 17 (13.4%) 20 (15.7%)
Gender
Male 78 (53.5%) 56 (62.2%) 10 (58.8%) 12 (60%
Female 49 (46.5%) 34 (37.8%) 7 (41.2%) 8 (40%)
M/F ratio 1.59 1.67 1.33 1.5
Age at onset of HD (years)
Mean±s.d. 61.6±14 61.2±13.4 63.3±14 62.9±17.4
Range 22–89 22–81 29–79 28–89
Median 63 63 65 65
Etiology of kidney disease
Diabetes mellitus 41 (32.3%) 32 (35.6%) 4 (23.55) 5 (25%)
Chronic pyelonephritis 15 (11.8%) 8 (8.9%) 3 (17.6%) 4 (20%)
Hypertension 13 (10.2%) 9 (10%) 3 (17.6%) 1 (5%)
Nephrolithiasis 12 (9.4%) 7 (7.7%) 2 (11.8%) 3 (15%)
Polycystic kidney 11 (8.7%) 7 (7.7%) 2 (11.8%) 2 (10%)
Glomerulonephritis 8 (6.3%) 6 (6.7%) 1 (5.9%) 1 (5%)
Unknown 27 (21.3%) 21 (23.3%) 4 (23.5%) 4 (20%)
Co-morbid condition
Ischemic heart disease 58 (45.7%) 35 (38.9%) 11 (64.7%) 12 (60%)
Diabetes mellitus 41 (32.3%) 27 (30%) 7 (41.2%) 7 (35%)
Hypertension 13 (10.2%) 5 (5.5%) 6 (35.3%) 2 (10%)
COPD 4 (3.1%) 2 (2.2%) 1 (5.9%) 1 (5%)
Medications
Beta blockers 69 (54.3%) 47 (52.2) 11 (64.7%) 11 (55%)
Calcium channel blockers 35 (27.5%) 22 (24.4%) 5 (29.4%) 8 (40%)
ACE inhibitors 91 (71.6%) 62 (68.9%) 15 (88.2%) 14 (70%)
Duration of HD (years)*
Mean±s.d. 4.7±2.4 5.9±2.7 4.1±2.9 4.4±3.4
Range 2–12 2–12 2–10 2–10
A-V access location
Brachial 37 (29.1%) 27 (30%) 7 (41.2%) 3 (15%)
Radial 90 (70.9%) 63 (70%) 10 (58.8%) 17 (85%)
Mortality* 77 (60.6%) 47 (52.2%) 14 (82.35%) 16 (80%)
ACE, angiotensin-converting enzyme; COPD, chronic obstructive pulmonary disease; HD, hemodialysis; PHT, pulmonary hypertension.
*Po0.05.
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and both had better cardiac status as compared with the
subgroup of patients with PHT prevalent before initiation of
HD (significantly lower frequency of significant valvular
abnormalities, left ventricular systolic dysfunction, and
segmental wall abnormalities).
Survival data
Survival data for all the patients and for subgroups of
patients without PHT and with PHT are presented in Tables 1
and 3 and in Figure 1. Subgroups of patients with PHT on
starting of HD therapy and with PHT incident after initiation
of HD therapy had a similar duration of HD therapy (or
follow-up), which was significantly shorter than that of their
counterparts without PHT (4.1±2.9 and 4.4±3.4 vs
5.9±2.7, respectively). The significantly shorter duration of
HD therapy among patients with PHT is attributed to the
survival disadvantage of this disease. Overall, 77 (60.6%)
patients died during the follow-up period. The 1-, 3-, and 5-
year survival rates were 90.6, 66.9, and 52.8%, respectively. As
a group, HD patients with PHT had significantly lower
survival rates compared with their counterparts without
PHT, as manifested by 1-, 3-, and 5-year survival rates of 78.6






after HD (n=20) ‘A’ vs ‘B’ ‘A’ vs ‘C’ ‘B’ vs ‘C’
Ischemic heart disease 35 11 12 NS NS NS
Echocardiographic abnormalities
Valvular
Mitral reg. mod-severe 9 (10%) 15 (88.2%) 2 (10%) o0.0001 NS P=0.008
Aortal reg. mod-severe 3 (3.3%) 2 (11.8%) 1 (5%) NS NS NS
Mitral stenosis mod-severe 0 0 0 NS NS NS
Aortic stenosis mod-severe 0 1 0 NS NS NS
Left ventricular
Dilatationa 32 (35.6%) 16 (94.1%) 5 (25%) 0.06 NS NS
Hypertrophyb 43 (47.8%) 11 (64.7%) 6 (30%) NS NS NS
Systolic dysfunctionc 11 (12.2%) 15 (88.2%) 0 o0.0001 NS 0.004
Diastolic dysfunction 26 (28.9%) 7 (41.2%) 5 (25%) NS NS NS
Segmental abnormalities 20 (22.2%) 13 (76.5%) 2 (10%) 0.02 NS 0.058
HD, hemodialysis; NS, not significant (P40.05); PHT, pulmonary hypertension.
aCavity volume 490ml/m2.
bMass index 4100g/m2 (females) 4130g/m2 (males).
cFractional shortening o25%.
Table 3 | Comparison of data between survivors and
non-survivors
Variable Died (n=77) Lived (n=50) P-value
Gender
Male 39 29
Female 38 21 0.5
Age at onset of HD
(Mean±s.d., years) 66.6±10.8 52.5±15.3 o0.0001
No. of patients 463 years 48 15 0.0005
Dialysis access
Radial 19 18 0.23
Brachial 58 32
PHT 445 mm Hg
Prevalent before HD 14 3 0.03
Incident after HD 16 4 0.03
Diabetes mellitus 27 14 0.7
Cardiac status
Ischemic heart diseases 41 17 0.248
Left ventricular dysfunction 18 8 0.547






















Figure 1 | Survival curves. The survival curves of the subgroups
of patients without and with pulmonary hypertension (PHT)
prevalent before or incident after onset of hemodialysis. Sub-
groups of patients with PHT had similar survival curves, which
were significantly lower when compared with patients without
PHT. HD, hemodialysis; PHT, pulmonary hypertension.
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vs 96.5, 42.9 vs 78.8, and 25.2 vs 66.4%, respectively (log-rank
P¼ 0.0001). Subgroups of patients with PHT incident after
initiation of HD therapy and with PHT present before
initiation of HD therapy had similar survival curves, and
both had lower survival rates as compared with patients
without PHT (log-rank P¼ 0.006 for the comparison of
patients without PHT and patients with PHT occurring after
the initiation of HD and o0.0001 for the comparison of
patients without PHT and patients with PHT present before
the initiation of HD; Figure 1).
Non-survivors were significantly older on initiating HD
(66.6±10.8 vs 52.5±15.3, Po0.0001), and had a signifi-
cantly higher prevalence of PHT (30 vs 7, P¼ 0.035), either
incident after (16 vs 4, P¼ 0.03) or prevalent at (14 vs 3,
P¼ 0.03) initiation of HD therapy.
The survival of 20 HD patients without PHT who matched
the group of patients with PHT incident after initiation of
HD therapy in their age, gender, etiology of kidney disease,
location of A-V access, and co-morbidities was significantly
longer, P¼ 0.0012 in the log-rank test.
The results of the univariable analysis for predictors of
mortality for the whole study population are shown in
Table 4. The age at onset of HD therapy, and presence of
significant valvular disease and PHT either prevalent before
or incident after initiation of HD therapy were associated
with an increased risk of death. Gender, DM, any parameter
of left ventricular dysfunction alone or in combination, and
location of A-V access were not associated with increased
mortality rates.
In a multivariable Cox proportional hazard model, PHT
remained the only independent predictor of all-cause
mortality (Table 4). Compared with patients without PHT,
the adjusted hazard ratios for mortality were 3.6 for PHT
present before initiation of HD (95% CI 1.8–7.0, P¼ 0.0002)
and 2.1 for PHT that developed after the initiation of HD
(95% CI 1.1–4.1, P¼ 0.02). Using pulmonary pressure as a
continuous variable in the whole study population, the
adjusted hazard ratio (HR) for mortality was 1.5 for each
10 mm Hg increase in PAP (95% CI 1.2–1.9, P¼ 0.0007).
DISCUSSION
Earlier studies have shown that the most common predictors
of adverse outcome among the population of HD patients
were age at onset of HD therapy and the extent of
co-morbidities.7 Analysis of this single-center cohort of 127
ESRD patients (33% with PHT) undergoing HD therapy
through A-V access confirmed these findings. Age at
initiation of HD therapy (HR: 1.7) and presence of
significant valvular dysfunction, and moderate to severe
regurgitation of the mitral and/or the aortic valve (HR 1.8)
were the leading conditions with increased risk for death
among this study population.
Diabetes mellitus, a well-recognized threat and a poor
prognostic factor among HD patients, was not associated
with an increased risk of death in this cohort, probably
because of the small sample size. The more speculative option
that HD patients with diabetes mellitus complications do not
tend to develop PHT has yet to be proven.
This study has confirmed our earlier observation that in
the population of HD patients, presence of PHT is associated
with a significantly greater risk of death. The 1-, 3-, and 5-
year survival rates of patients with and without PHT were
78.6 vs 96.5, 42.9 vs 78.8, and 25.2 vs 66.4%, respectively.
Similar to other conditions, such as collagen vascular
diseases, in which PHT is associated with a survival
disadvantage, mortality rates of HD patients with PHT
exceed those of their counterparts without PHT.8,9 Of note,
subgroups of patients with PHT prevalent before and
incident after initiation of HD therapy had similar survival
curves, which were significantly shorter compared with their
counterparts without PHT.
Cardiac dysfunction, a common co-morbid condition in
ESRD patients and the most common cause of PHT, was
frequent in the study population. Detailed analysis has shown
that the subgroups of patients with PHT incident after
initiation of HD and without PHT at any time had similar
cardiac status. Both subgroups had significantly better
cardiac status as manifested by significantly lower frequency
of valvular abnormalities and left ventricular dysfunctions as
compared with the sub-group of patients with PHT prevalent
on entering HD therapy. In a uni-variant and a multi-variant
analysis of the whole study population, only the valvular
abnormalities had reached the level of statistical significance.
This study stratifies two phenotypes of pre-dialysis
patients, without and with PHT. In the former, some patients
(subgroup ‘C’) develop unexplained PHT after receiving A-V
access and initiating HD therapy. In an attempt to disclose
masked cardiac dysfunction as a cause for this entity, we
Table 4 | Univariable and multivariable Cox regression models for death
Univariable Multivariable
Hazard ratio (95% CI) P (v2) Hazard ratio (95% CI) P (v2)
Age at onset of HD (per 10 years increase) 1.7 (1.3–2.1) o0.0001 1.6 (1.3–2.0) o0.0001
Valvular disease 1.8 (1.0–3.1) 0.049 0.9 (0.5–1.7) 0.91
PHT
No PHT 1.0 (Referent) — 1.0 (Referent) —
Present before HD 3.6 (1.9–4.8) o0.0001 3.6 (1.8–7.0) 0.0002
Incident after HD 2.4 (1.2–4.5) 0.009 2.1 (1.1–4.3) 0.02
CI, confidence interval; HD, hemodialysis; PHT, pulmonary hypertension.
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compared the cardiac status of the patients with PHT
incident after initiation of HD with that of their counterparts
without PHT at any time and found no difference. Thus we
may assume that this entity cannot be attributed to existing
cardiac abnormality.
In a multi-variant analysis, the HRs for death of ESRD
patients with PHT incident after initiation of HD therapy
and with PHT prevalent on initiation of HD therapy were 3.6
and 2.1, respectively. In other words, the risk of death for
ESRD patients in whom PHT incident after A-V access
formation and initiation of HD therapy was close to
that of their counterparts who entered the HD program
with PHT that is associated with long-standing severe cardiac
dysfunction.
The entity of PHT in ESRD incidents after initiation of
HD therapy is relatively new. In an earlier study, we reported
a shorter life expectancy among HD patients with PHT.1
However, we had some concerns regarding the findings,
mostly because of the small sample size. This study extends
our former observation that the development of PHT after A-
V access formation and initiation of HD therapy is associated
with a survival disadvantage.
The demonstration that PHT incident after onset of HD
therapy is a strong independent risk factor for death has
significant clinical implication. On one hand, HD therapy
prolongs the lives of ESRD patients. On the other hand, some
ESRD patients do not tolerate the hemodynamic changes in
the area of the HD therapy through a surgically created A-V
access and develop PHT with exceedingly high mortality
rates.
The relatively small number of patients and the retro-
spective nature of this study carry a risk for bias. Statistical
analysis for the entire study population and a sub-population
analysis as well as matched analysis showed consistently that
PHT either prevalent before or incident after initiation of HD
therapy is a strong independent predictor for death.
In attempting to validate the findings of this study, we
compared the epidemiological features of the study popula-
tion with the data recorded on 10,000 HD patients from the
Israel Center for HD Therapy and Kidney Transplantation
Registry. The patient gender, age distribution, etiology of
ESRD, and distribution of co-morbid conditions were
similar. For example, the male:female ratio of 1.59 vs 1.56,
mean and median ages at initiation of HD therapy of 61.6
and 63 years vs 63.5 and 67.3 years assured that the sample of
patients included in the study is representative of the
population of HD patients. However, it should be noted
that the 1-, 3-, and 5-year mortality rates of the study
population were significantly lower than those recorded in
the national registry (9.4 vs 19, 33.1 vs 42.6, and 47.2 vs
65%), probably reflecting a single center’s experience with a
limited number of patients. Alternately, it might express
better supportive medical care and improving dialysis
techniques.
Many studies have looked at the predictors of mortality
among ESRD patients on HD therapy.10–12 Most incorporate
into the survival analysis, in addition to epidemiological and
clinical parameters, biochemical variables that reflect the
quality of the HD therapy as well as the supportive care. As
our study pertains to the impact of PHT on the outcome of
ESRD patients on HD therapy at a single HD center
providing therapy during a single decade, we felt that adding
biochemical parameters to the survival analysis would not
add to the understanding of this phenomenon.
PHT in HD patients has some unique characteristics that
differ from other forms of the disease.13,14 PAP values tend to
regress after temporary closure of the A-V access (reduction
of CO) or after successful kidney transplantation (ameliora-
tion of uremia). In earlier studies, we showed that the
pathogenesis of this syndrome is uremic-induced endothelial
dysfunction that reduces the ability of the pulmonary
vasculature to accommodate the A-V access-mediated
elevated CO results in the development of PHT.
Clinical significance
The presence of PHT in ESRD patients presents a therapeutic
dilemma, as it is associated with significantly increased
mortality rates. Patients entering the HD program should be
screened for PHT before entering the program and on an
annual basis thereafter. For patients with pre-existing PHT,
kidney transplantation should be considered. The dilemma of
PHT that is incident after initiation of HD therapy is more
complicated. This form of PHT is generated by the life-saving
HD therapy on the one hand and is associated with survival
disadvantage on the other hand. In this set-up, screening of
ESRD patients scheduled for initiation of long-term HD for
sub-clinical PHT is recommended. The reversibility of this
form of PHT following kidney transplantation is encoura-
ging, and patients with significant PHT incident after
initiation of HD therapy should be encouraged to seek a
transplant. Surgical reduction of oversized A-V access should
be considered in patients with PHT and extremely high CO
who show a reduction of both CO and PHT values following
temporary closure of their A-V access in the echocardio-
graphy laboratory. Peritoneal dialysis, another therapeutic
alternative in some patients, is not attractive as recent studies
have shown that the survival curves of patients with this
mode of renal replacement therapy is similar to the survival
curves of HD patients.12
MATERIALS AND METHODS
Study population
Patients’ selection. A list of all patients undergoing
chronic HD therapy in the Dialysis Unit at Rambam Health
Care Campus, a 900-bed primary and tertiary, university-
affiliated hospital, from 1995 to 2005 was retrieved from the
computerized hospital database. Patients were included in the
study if they had at least two Doppler echocardiography
studies, one of them carried out before and another one after
initiation of HD therapy. Patients with only one echo study
were also eligible, if the echo study was carried out after
initiation of HD therapy and had shown normal PAP values,
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assuming that the pre-HD PAP values were normal. The
study was approved by the local institutional review board.
Patient evaluation. Demographic data (age, gender,
co-morbid conditions, and medications used) and data
regarding kidney disease status: etiology of renal failure, A-V
access formation date, access location (brachial, radial), and
date of onset of HD therapy, were recorded. Co-morbid
conditions were documented by a consultant nephrologist from
the HD unit (FN) who was familiar with the patient’s case
history from the dialysis unit records, hospital discharge
summaries, medication lists, consultation notes, and results of
imaging tests. To be considered, the co-morbid condition had to
be active, or currently controlled with ongoing treatment.
The following domains of active co-morbid disease were
considered:
(1) Ischemic heart disease—As evidenced by earlier myo-
cardial infarction, angina pectoris, positive coronary
angiography, positive exercise or thallium or dobutamine
stress test, echocardiographic evidence of left ventricular
wall segmental abnormalities.
(2) Left ventricular dysfunction—a history of pulmonary
edema and/or moderate to severe left ventricular
dysfunction defined as echocardiographic or left ven-
tricular fractional shortening o25%.
(3) Peripheral vascular disease including aorta, renal, lower
limb, and cerebral–vascular disease either symptomatic
(CVA, claudicating, amputation) or of significant
stenosis (470%) on vascular imaging or Doppler
ultrasound.
(4) Diabetes mellitus type I or type II.
(5) Collagen vascular disease, such as systemic vasculitis,
scleroderma, systemic lupus erythematosis, and rheu-
matoid arthritis, either active or requiring treatment.
(6) Other significant pathology severe enough to affect
survival in the general population, such as chronic
obstructive pulmonary disease, psychotic illness, cirrho-
sis, peptic ulcer, etc.
Echocardiography. The patients underwent a standard
2D, M-mode, Doppler echocardiography study within 2 h
from the end of HD therapy while they were as close as
possible to their dry weight. The form presented to the
echocardiographist noted that the patient was receiving HD
therapy, but it was not noted whether he/she had A-V access
elsewhere. A tricuspid regurgitation systolic jet was recorded
from the parasternal or apical window with the continuous-
wave Doppler echocardiography probe. Systolic right ven-
tricular (or pulmonary artery) pressure was calculated using
the modified Bernoulli equation: PAP¼ 4 (tricuspid
systolic jet)2þ 10 mm Hg (estimated right atrial pressure).15
The accuracy of systolic PAP estimation by Doppler
echocardiography in our laboratory has been published
earlier.16 PHT was defined as a systolic PAP of more than
45 mm Hg. The patients were categorized into three sub-
groups according to timing of PHT onset:
Sub-group ‘A’—No PHT at any time.
Sub-group ‘B’—PHT present before starting HD therapy.
Sub-group ‘C’—PHT incident after initiation of HD
therapy.
Records of patients with PHT incident after initiation of
HD therapy were evaluated by a consultant pulmonologist
(MY) to uncover potential causes of PHT. This included
history, physical examination, chest radiograph and CT,
pulmonary function tests, arterial blood gases and oxygen
saturation, and ventilation–perfusion lung scan.
The echocardiographic findings were categorized accord-
ing to the following list17:
(1) Significant valvular abnormality—moderate to severe
stenosis and/or regurgitation of mitral and/or of the
aortic valve.
(2) Left ventricular abnormality:
a. Left ventricular dilatation—cardiac cavity 490 ml/m2.
b. Left ventricular hypertrophy—(mass index 4100 g/
m2 (females), 4 131 g/m2 (males)).
c. Left ventricular systolic dysfunction—fractional
shortening p25%.
d. Left ventricular diastolic dysfunction.
(3) Left ventricular wall segmental abnormalities.
To investigate the etiology of PHT incident after initiation
of HD therapy, the frequencies of the above-mentioned
cardiac abnormalities were compared between this subgroup
of patients and the sub-groups of patients without PHT and
with PHT prevalent before starting HD.
Follow-up. The follow-up period was calculated from the
onset of HD therapy to death. For survivors, 31 December
2007 was the last day of follow-up.
Data analysis. The differences between survivors and
non-survivors were assessed using t-test for continuous
variables and the chi-square test for categorical variables.
Mortality data were expressed by the Kaplan–Meier survival
curves and were compared using the log-rank test. The effect
of prognostic factors on mortality was assessed within the
whole population and for the three subgroups of patients:
without PHT (reference group), with PHT present on
initiation of HD and with PHT incident after initiation of
HD therapy. To overcome the statistical error due to patients’
variance we compared the survival of 20 HD patients without
PHT who matched the group of patients with PHT incident
after initiation of HD therapy in their age, gender, etiology of
kidney disease, location of A-V access, and co-morbidities.
The association between clinical and hemodynamic
variables and mortality was first evaluated using a
uni-variable Cox proportional hazards model. The variables
analyzed were predictors of adverse outcome from the
literature, such as age, gender, etiology of ESRD, duration
of HD therapy, A-V access location, co-morbid diseases,
parameters of cardiac status (ischemic heart disease,
significant valvular abnormalities, left ventricular dysfunc-
tion), presence and severity of PHT, and timing of PHT onset
(before or incident after initiation of HD therapy). There-
after, the Cox proportional hazards model was applied for the
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multi-variant regressions of the variables found to be associated
with death in the uni-variable model at the Po0.1 level. The
HR for death and a 95% confidence interval were calculated.
Differences were considered statistically significant at the two-
sided Po0.05 level. Statistical analyses were carried out using
the SPSS statistical package (Version 15.0).
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